Get the Stockscreener App
10.28
2.37%
-0.25
After Hours:
10.31
0.03
+0.29%
Oric Pharmaceuticals Inc stock is traded at $10.28, with a volume of 1.78M.
It is down -2.37% in the last 24 hours and down -13.61% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$10.53
Open:
$10.51
24h Volume:
1.78M
Relative Volume:
0.87
Market Cap:
$1.15B
Revenue:
-
Net Income/Loss:
$-129.47M
P/E Ratio:
-6.7873
EPS:
-1.5146
Net Cash Flow:
$-114.08M
1W Performance:
+13.59%
1M Performance:
-13.61%
6M Performance:
-26.04%
1Y Performance:
+103.97%
1-Day Range:
$10.01
$10.69
1-Week Range:
$8.90
$10.93
52-Week Range:
$4.52
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
10.28 | 1.18B | 0 | -129.47M | -114.08M | -1.5146 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Nov-20-25 | Initiated | Evercore ISI | Outperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - ChartMill
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Positive Phase 1b Rinzimetostat Trial Update - Sahm
ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN
Why ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial - Sahm
Understanding the Setup: (ORIC) and Scalable Risk - Stock Traders Daily
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation - Moomoo
Oric Pharmaceuticals Stock Rises 6.5%, Analysts Maintain Buy Ratings - National Today
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.5%Still a Buy? - MarketBeat
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $25 - Moomoo
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Advancing Rinzimetostat To A Phase 3 Prostate Cancer Trial - Sahm
ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to - GlobeNewswire
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data - Yahoo Finance
ORIC Pharmaceuticals Reports Inducement Grants - National Today
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance UK
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
ORIC Pharmaceuticals (ORIC) Is Down 28.2% After Selecting 400 mg Rinzimetostat Dose for Phase 3 - Sahm
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sahm
ORIC Pharmaceuticals Faces Volatile Trading Following Latest Clinical Trial Developments - StocksToTrade
ORIC Pharmaceuticals’ Global Ambitions amid Tumultuous Share Movements - StocksToTrade
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% HigherTime to Buy? - MarketBeat
ORIC Pharmaceuticals Faces Turbulence Amid Prostate Cancer Drug Advancements - timothysykes.com
Investors Purchase Large Volume of Oric Pharmaceuticals Call Options (NASDAQ:ORIC) - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Ta - GuruFocus
HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - marketbeat.com
Oric Pharmaceuticals stock falls on prostate cancer trial data, Sellside Comments - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock - Investing.com
Guggenheim Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC) - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Target | ORIC Stock News - GuruFocus
ORIC Stock Pullback Seen as Buying Opportunity - GuruFocus
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 - Yahoo Finance
ORIC Pharmaceuticals Inc. R (4TZ.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
What's Behind The Drop In Oric Pharmaceuticals Stock Today? - Sahm
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC: Opportunity Arises in Oric Pharmaceuticals Amid Price Drop - GuruFocus
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oric Pharmaceuticals Inc Stock (ORIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Feb 24 '26 |
Sale |
13.51 |
52,000 |
702,686 |
68,148 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):